Last updated: 2026-09-09 04:51:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Korro Bio, Inc. (KRRO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $13.51, with a market capitalization of $180.24M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.20 to $55.89. This page covers its latest market performance, valuation, price trends and company information.
$180.24M | |
$12.03 | |
$98.00 | |
$5.20 | |
$12.24 | |
109.55K | |
176.23K | |
-- | |
$55.89 | |
$5.20 | |
-- | |
-- |
Korro Bio, Inc. (KRRO) last closed at $12.24 as of 2026-09-08 23:31:00, unchanged from the previous close of $12.24.
During the latest regular trading session, KRRO traded between $5.20 and $98.00, with a volume of 109.55K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Korro Bio, Inc. (KRRO) moved from $13.26 to $13.51, representing a gain of 1.87% ($0.25).
The stock traded between $11.30 and $13.69 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 72.16 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 16.4%
KRRO is currently trading at $13.51, placing it 16.4% of the way from its 52-week low of $5.20 to its 52-week high of $55.89. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 57 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Korro Bio, Inc. (KRRO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.